Media stories about EyeGate Pharma (NASDAQ:EYEG) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EyeGate Pharma earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.8395860192766 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
A number of research analysts have recently issued reports on EYEG shares. HC Wainwright set a $3.00 price target on EyeGate Pharma and gave the company a “buy” rating in a report on Tuesday, April 24th. ValuEngine upgraded EyeGate Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
EyeGate Pharma traded up $0.03, hitting $0.62, on Friday, Marketbeat Ratings reports. 1,342,756 shares of the company’s stock were exchanged, compared to its average volume of 1,405,591. EyeGate Pharma has a 12-month low of $0.29 and a 12-month high of $2.43. The company has a market cap of $32.99 million, a price-to-earnings ratio of -0.61 and a beta of 3.52.
EyeGate Pharma (NASDAQ:EYEG) last announced its earnings results on Friday, March 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. EyeGate Pharma had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. sell-side analysts predict that EyeGate Pharma will post -0.6 EPS for the current year.
In other news, major shareholder Armistice Capital Master Fund purchased 10,479,970 shares of the stock in a transaction on Tuesday, April 17th. The stock was bought at an average price of $0.36 per share, with a total value of $3,772,789.20. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have purchased 13,509,970 shares of company stock worth $5,265,819. 24.60% of the stock is owned by company insiders.
EyeGate Pharma Company Profile
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Receive News & Ratings for EyeGate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyeGate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.